Autoantigen-Specific Regulatory T Cell Induction for Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like Type 1 diabetes suppress all immune responses, leading to long-term toxicities and the loss of protective immune responses against pathogens, and existing therapies for Type 1 diabetes require daily insulin injections with concerns about hypoglycemia and do not effectively restore immune tolerance to specific autoantigens.
Innovation Solution
Induction of insulin autoantigen-specific regulatory T cells by administering insulin B-chain in a water-in-oil emulsion adjuvant to induce a robust Th-2 biased immune response, maintaining therapeutic levels through booster doses, which helps in suppressing autoimmune destruction of pancreatic beta cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general immune suppression is used to treat autoimmune disease, then autoimmune progression is slowed, but protective immune responses against pathogens are suppressed and long-term toxicities occur
Solution Approach 1:
The treatment is segmented into two distinct components: (1) administration of the specific autoantigen to induce antigen-specific regulatory T cells, and (2) use of a Th-2 biased adjuvant to enhance the regulatory response. This segmentation allows selective induction of tolerance to the specific autoantigen while preserving general immune function against pathogens.
Solution Approach 2:
The invention applies local quality by creating a localized immune response specifically targeted at the autoantigen. The adjuvant is designed to bias the immune response toward Th-2 cytokine production at the injection site and draining lymph nodes, inducing regulatory T cells that specifically recognize the autoantigen without broadly suppressing the immune system.
2Reliability
If insulin therapy is used to treat Type 1 diabetes, then blood glucose control is improved, but concerns about hypoglycemia arise and residual beta cell function is not preserved
Solution Approach 1:
The invention applies preliminary action by administering the autoantigen-based vaccine to induce regulatory T cells before complete beta cell destruction occurs. This early intervention aims to restore immune tolerance and preserve residual beta cell function, potentially delaying or preventing the need for exogenous insulin therapy.
Solution Approach 2:
The invention converts the harmful autoimmune response against beta cells into a beneficial therapeutic effect. By using the autoantigen (insulin or insulin B-chain) as a vaccine component with Th-2 biased adjuvant, the harmful autoimmune attack is redirected into a protective regulatory T cell response that suppresses the pathological autoimmune destruction of beta cells.
3Reliability
If autoantigen is reintroduced in incomplete Freund's adjuvant, then immune response is enhanced in animal models, but the approach has not been successfully translated to human therapy
Solution Approach 1:
The invention applies parameter changes by modifying the adjuvant properties to create a Th-2 biased immune response profile. Instead of using the standard incomplete Freund's adjuvant formulation, the patent uses adjuvants specifically selected and optimized to induce Th-2 cytokine production (IL-4, IL-5, IL-13) and regulatory T cell generation, which has been shown to be more effective in human clinical trials for inducing immune tolerance.
Data Source
AI summary
Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.